My name is Eric Baker. I am actually reaching out for more than one reason, as from a very young age I have had optic nerve atrophy, which has left me legally blind. But that has not stopped me from wanting to follow my dreams, do big things, and also help others in some way, [Read More]
News
Muhammad’s Story
by Muhammad Hassan Rasheed Diagnosis I’ve had an eye problem since birth. When I was around four months old, my family noticed something wasn’t right. When I used to crawl, I would bump into things, which made them think I might have a vision issue. They took me to the doctor, and that’s when we [Read More]
Important Accessibility Bill Seeking Congressional Support
The American Council of the Blind (ACB) has announced that the Website and Software Applications Accessibility Act has once again been introduced in the House of Representatives on Wednesday, May 14. This was a wonderful way to usher in Global Accessibility Awareness Day (GAAD) on Thursday, May 15. The bill was introduced by Republican Congressman [Read More]
New Drug Approved for Treatment of Macular Telangiectasia Type 2 (MacTel)
Neurotech Pharmaceuticals, Inc. has announced FDA approval of ENCELTO (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia type 2 (MacTel). ENCELTO is the First and Only FDA-approved first and only treatment for MacTel. MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly impacting patients’ quality of [Read More]
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo may help people with DME maintain their vision Approval marks the second indication for Susvimo in addition to wet, or neovascular age-related macular [Read More]